How much funding has Lazarus 3D raised?

Lazarus 3D has raised $12.09M in total funding. Key investors include Ecliptic Capital, Alliance of Angels, Mentors Fund, Revolution, Capital Factory.

Who is the CEO of Lazarus 3D?

Jacques Zaneveld is the CEO of Lazarus 3D. The company was founded in 2014.

Where is Lazarus 3D located?

Lazarus 3D is headquartered in Philomath, Oregon, USA.

What funding stage is Lazarus 3D at?

Lazarus 3D is currently at the Active stage.

How many employees does Lazarus 3D have?

Lazarus 3D has approximately 11-50 employees.

Lazarus 3D

Name: AM Companies Database
Creator: AMPulse
License: https://creativecommons.org/licenses/by/4.0/

ApplicationPhilomath, Oregon, USAFounded 2014· One of 381 Application companies tracked by AMPulse

FDA-cleared 3D printed anatomical models enabling surgeons to rehearse on exact patient organ replicas

CEO / Founder: Jacques Zaneveld
Team Size: 11-50
Stage: Active
Total Funding: $12.09M
Key Investors: Ecliptic Capital, Alliance of Angels, Mentors Fund, Revolution, Capital Factory

Technology & Products

Key Products

Lazarus 3D offers Preoperative Surgical Rehearsal (Pre-Sure) platform, a diagnostic tool for surgical planning that provides surgeons with soft-tissue anatomical models for rehearsal. They create patient-specific replicas of organs like the brain, heart, lungs, and bladder using 3D printing.

Technological Advantage

Proprietary technology for creating realistic organ replicas from patient imaging data

Differentiation

Value Proposition

Enable surgical perfection through exact replicas of patients' organs for pre-operative rehearsal

How They Differentiate

Focus on surgical rehearsal with realistic tissue properties

Market & Competition

Target Customers

Surgeons, hospitals, medical education institutions

Industry Verticals

Healthcare, Medical Devices, Surgical Training

Competitors

Stratasys, 3D Systems, Axial3D, Materialise

Growth & Milestones

Growth Metrics

NIH awards including $371K in 2023, Business Oregon grants

Major Milestones

2014: Founded in Houston TX, FDA clearance for Pre-Sure, $6M seed led by Ecliptic Capital, 2023: $371K NIH award, Relocated to Oregon

Notable Customers

The Cleveland Clinic and over two dozen other hospitals and medical providers.

https://laz3d.com

Why this company matters

Lazarus 3D occupies a narrow but high-value niche within medical additive manufacturing: producing FDA-cleared, patient-specific anatomical models that mimic the mechanical properties of real soft tissue. While most 3D-printed medical models are used for visualization or education, Lazarus 3D's Pre-Sure platform is designed as a diagnostic tool for pre-operative surgical rehearsal, allowing surgeons to practice on exact replicas of a patient's brain, heart, lungs, or bladder before the actual procedure.

The company's core technology converts standard CT and MRI scans into physical models using polymer additive manufacturing. Its proprietary process aims to replicate the tactile feel of human tissue, a critical factor for rehearsal fidelity. Lazarus 3D holds an active patent covering methods and systems for creating these anatomical models, and its Pre-Sure technology has received FDA clearance, a regulatory barrier that limits direct competition from general-purpose 3D printing service bureaus.

Customers include The Cleveland Clinic and more than two dozen other hospitals and medical providers. The models are used across multiple surgical specialties, including cardiothoracic, neurosurgery, and urology. Lazarus 3D has raised approximately $12 million from investors including Ecliptic Capital, Alliance of Angels, and Capital Factory, and has received NIH awards and Business Oregon SBIR/STTR grants to support continued development.

The competitive landscape includes larger players like Stratasys, 3D Systems, and Materialise, as well as specialized firms such as Axial3D. Lazarus 3D differentiates by focusing exclusively on surgical rehearsal with realistic tissue properties rather than on general anatomical visualization. The key open question is whether the company can scale its hospital-by-hospital sales model and build a recurring revenue stream from procedure-specific model orders, or whether it will remain a niche tool for complex cases at leading academic medical centers.